Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations

被引:94
|
作者
Arendrup, Maiken Cavling [1 ]
Perlin, David S. [2 ]
Jensen, Rasmus Hare [1 ]
Howard, Susan Julie [3 ]
Goodwin, Joanne [3 ]
Hope, William [3 ]
机构
[1] Statens Serum Inst, Unit Mycol & Parasitol, DK-2300 Copenhagen, Denmark
[2] UMDNJ New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ USA
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester, Lancs, England
基金
美国国家卫生研究院;
关键词
INVASIVE CANDIDIASIS; REDUCED SUSCEPTIBILITY; AMPHOTERICIN-B; ALBICANS; TROPICALIS; ECHINOCANDINS; SUBSTITUTIONS; EPIDEMIOLOGY; ESOPHAGITIS; FLUCONAZOLE;
D O I
10.1128/AAC.06369-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half-and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg . h/liter, respectively. In contrast, the maximum effect (E-max) for caspofungin was higher against S3 than R83, but the estimates for E-50 were similar (187.1 and 203.5 mg . h/liter, respectively). Anidulafungin failed to induce a >= 1-log reduction for any of the isolates (AUC range, 139 to 557 mg . h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.
引用
收藏
页码:2435 / 2442
页数:8
相关论文
共 50 条
  • [1] Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying FKS Mutant Candida glabrata Strains and Echinocandin Resistance
    Shields, Ryan K.
    Nguyen, M. Hong
    Press, Ellen G.
    Updike, Cassaundra L.
    Clancy, Cornelius J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6361 - 6365
  • [2] In Vitro Fungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies
    Gil-Alonso, Sandra
    Jauregizar, Nerea
    Canton, Emilia
    Eraso, Elena
    Quindos, Guillermo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3615 - 3618
  • [3] Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit
    Ghannoum, M. A.
    Chen, A.
    Buhari, M.
    Chandra, J.
    Mukherjee, P. K. .
    Baxa, D.
    Golembieski, A.
    Vazquez, J. A.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (03) : 274 - 279
  • [4] In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility
    Cota, Jason
    Carden, Michael
    Graybill, John R.
    Najvar, Laura K.
    Burgess, David S.
    Wiederhold, Nathan P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (11) : 3926 - 3928
  • [5] Innate Inflammatory Response and Immunopharmacologic Activity of Micafungin, Caspofungin, and Voriconazole against Wild-Type and FKS Mutant Candida glabrata Isolates
    Beyda, Nicholas D.
    Liao, Guangling
    Endres, T.
    Lewis, Russell E.
    Garey, Kevin W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) : 5405 - 5412
  • [6] Eagle effects with Caspofungin and Micafungin, but not with Anidulafungin with clinical isolates of Candida albicans and Candida dubliniensis
    Fleischhacker, M.
    Radecke, C.
    Weber, K.
    Schulz, B.
    Ruhnke, M.
    MYCOSES, 2007, 50 (05) : 368 - 368
  • [7] Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata
    Spreghini, Elisabetta
    Orlando, Fiorenza
    Sanguinetti, Maurizio
    Posteraro, Brunella
    Giannini, Daniele
    Manso, Esther
    Barchiesi, Francesco
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (03) : 1215 - 1222
  • [8] Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis
    Smith, Raymond P.
    Baltch, Aldona
    Bopp, Lawrence H.
    Ritz, William J.
    Michelsen, Phyllis P.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 71 (02) : 131 - 138
  • [9] In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera
    Wiederhold, Nathan P.
    Najvar, Laura K.
    Bocanegra, Rosie
    Molina, Destiny
    Livo, Marcos
    Graybill, John R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (05) : 1616 - 1620
  • [10] Antifungal susceptibility testing of micafungin against Candida glabrata isolates
    Oliveira, Erica R.
    Fothergill, Annette
    Kirkpatrick, William R.
    Patterson, Thomas F.
    Redding, Spencer W.
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2008, 105 (04): : 457 - 459